Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC

J Thorac Oncol. 2024 Mar;19(3):380-384. doi: 10.1016/j.jtho.2023.12.018.

¹ Division of Hematology-Oncology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.
² University of California Irvine School of Medicine, Orange, California.
³ Division of Hematology-Oncology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York; University of California Irvine School of Medicine, Orange, California; Chao Family Comprehensive Cancer Center, Orange, California.
⁴ University of California Irvine School of Medicine, Orange, California; Chao Family Comprehensive Cancer Center, Orange, California. Electronic address: siou@hs.uci.edu.

No abstract available

Publication types